Impax Laboratories Inc (IPXL.OQ)
20.98USD
2:58pm EDT
$0.15 (+0.72%)
$20.83
$20.80
$21.02
$20.74
48,476
286,146
$27.25
$14.41
About
Overall
| Beta: | 0.32 |
| Market Cap (Mil.): | $1,426.38 |
| Shares Outstanding (Mil.): | 68.48 |
| Dividend: | -- |
| Yield (%): | -- |
Financials
| IPXL.OQ | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | 9.55 | 38.06 | 37.87 |
| EPS (TTM): | 2.18 | -- | -- |
| ROI: | 19.96 | 19.42 | 18.70 |
| ROE: | 20.91 | 20.10 | 19.53 |
Impax, GSK end Parkinson's disease partnership
- Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.
Impax, GSK end Parkinson's disease partnership
April 29 - Impax Laboratories Inc said partner GlaxoSmithKline Plc ended their collaboration on Impax's experimental Parkinson's disease drug due to regulatory and launch delays in the countries in which GSK has rights to market the drug.
Impax shares drop as FDA flags new concerns on manufacturing plant
- Impax Laboratories Inc said U.S. health regulators raised fresh concerns related to manufacturing practices at the drugmaker's Hayward, California facility, sending its shares down more than 20 percent after the bell.
BRIEF-Shire, Impax settle litigation related to Adderall XR
LONDON, Feb 8 - Shire PLC : * Unit has settled all pending litigation with Impax Laboratories * Litigation was over shire's supply of an authorized generic version of
Competitors
| Price | Change | |
|---|---|---|
| Ranbaxy Laboratories Limited (RANB.NS) | Rs273.10 | +10.75 |
| Teva Pharmaceutical Industries Limited (TEVA.TA) | 13,920.00₪ | -200.00 |
| Mylan Inc. (MYL.OQ) | $36.04 | +2.05 |
| Actavis Inc (ACT.N) | $135.60 | -0.18 |
| Lannett Company, Inc. (LCI.A) | $13.98 | +0.01 |
Earnings vs.
Estimates
Analyst Research Reports
| Report Title | Price |
|---|---|
|
Provider: Thomson Reuters Stock Report
|
$25.00
|
|
Provider: ValuEngine, Inc.
|
$25.00
|
|
Provider: Wright Reports
|
$472.00
|
|
Provider: Pechala's Reports
|
$15.00
|
|
Provider: Reuters Investment Profile
|
$20.00
|
NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

